Abstract
A 52 year-old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproferative disorder.
| Original language | English |
|---|---|
| Pages (from-to) | 411-419 |
| Number of pages | 9 |
| Journal | Leukemia and Lymphoma |
| Volume | 39 |
| Issue number | 3-4 |
| DOIs | |
| Publication status | Published - 2000 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- CD20
- EBV
- Immunosuppression
- Organ
- Post transplant lymphoproliferative disorder
- Rituximab
- Treatment
Fingerprint
Dive into the research topics of 'Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver